Buy Femilon

Femilon

What is Femilon?

Femilon is a combined oral contraceptive pill (COC) that contains two active ingredients: ethinylestradiol (0.15 mg) and desogestrel (0.02 mg). It belongs to the women’s health therapeutic class and is prescribed in the United Kingdom for the prevention of pregnancy and the management of several menstrual-related conditions. Femilon is supplied as a film-coated tablet, available in the 0.15/0.02 mg strength, and is approved for prescription use by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, the product is marketed by Aspen Pharma.

How Femilon Works in the Body

Femilon combines a synthetic estrogen (ethinylestradiol) with a synthetic progestogen (desogestrel). The estrogen component stabilises the uterine lining and suppresses the release of follicle-stimulating hormone (FSH), while the progestogen primarily inhibits luteinising hormone (LH) surge, preventing ovulation. In addition, desogestrel thickens cervical mucus, making it more difficult for sperm to reach an egg, and induces changes in the endometrium that reduce the likelihood of implantation. These synergistic actions provide reliable contraceptive protection when the pill is taken as directed.

Conditions Treated by Femilon

Femilon is approved by the MHRA for the following indications:

• Prevention of pregnancy in women of reproductive age who are not pregnant, breastfeeding, or intending to become pregnant.
• Regulation of menstrual cycles and reduction of dysmenorrhoea (painful periods).
• Management of acne and other androgen-related skin conditions when prescribed for this purpose.
• Treatment of endometriosis-related pelvic pain (as part of a broader therapeutic plan).

The primary patient population includes healthy women aged 15 years and older who have no contraindications to combined hormonal contraception.

Evidence-Based Off-Label Uses

Some clinicians prescribe combined oral contraceptives, including Femilon, for conditions that lie outside the formal label:

• Polycystic ovary syndrome (PCOS) - oral contraceptives are often used to regulate cycles and improve hirsutism in PCOS patients.
• Heavy menstrual bleeding - low-dose estrogen-progestogen combos can reduce menstrual blood loss.

These uses are supported by clinical guidelines and peer-reviewed studies, but they are not approved by the MHRA for Femilon specifically. Off-label treatment should be undertaken only under the supervision of a qualified healthcare professional, with individualized risk assessment.

Who Should (Not) Use Femilon?

Absolute Contraindications

• Known or suspected pregnancy.
• History of or current venous or arterial thromboembolism (deep-vein thrombosis, pulmonary embolism, stroke, myocardial infarction).
• Hormone-dependent malignancies (e.g., breast cancer, endometrial cancer).
• Severe uncontrolled hypertension (≥ 160/100 mm Hg).
• Congenital or acquired thrombophilia (e.g., protein C or S deficiency, antiphospholipid syndrome).
• Active liver disease or hepatic tumors.
• Known hypersensitivity to ethinylestradiol, desogestrel, or any tablet excipient.

Relative Contraindications

• Women over 35 years who smoke cigarettes.
• Migraine with aura.
• Diabetes mellitus with vascular complications.
• Moderate hepatic impairment.
• Lupus anticoagulant or other systemic autoimmune disorders.

Special Populations

• Pregnancy: Contraindicated; alternative contraception should be used.
• Breastfeeding: Typically avoided during the first six weeks postpartum; after this period, a healthcare professional may consider continued use.
• Post-menopausal hormone therapy: Not indicated.
• Older adults (> 55 years): Generally not recommended unless clear benefit outweighs risk.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or mild stomach upset.
• Breast tenderness or enlargement.
• Headache, including tension-type headache.
• Spotting or breakthrough bleeding, especially during the first 3 months of use.
• Mood changes or mild depressive symptoms.
• Decreased libido.

These effects are usually transient and may improve with continued use.

Serious Adverse Events

• Venous thromboembolism (VTE): Deep-vein thrombosis, pulmonary embolism.
• Arterial thromboembolism: Stroke, myocardial infarction.
• Severe hypertension or hypertensive crisis.
• Liver dysfunction (cholestatic jaundice, hepatic adenoma).
• Allergic reactions (rash, angioedema, anaphylaxis).

If any of these serious symptoms occur, seek emergency medical care immediately.

Drug Interactions

• Enzyme inducers (e.g., rifampicin, carbamazepine, phenytoin, St John’s wort) may reduce Femilon’s effectiveness, increasing the risk of pregnancy.
• Enzyme inhibitors (e.g., ketoconazole, itraconazole, HIV protease inhibitors) can raise hormone levels, potentially enhancing side-effects.
• Certain antibiotics (e.g., tetracycline, ampicillin) have been reported to interfere with contraceptive efficacy, although the evidence is limited; additional non-hormonal contraception is advisable during short-term use.
• Anticonvulsants and antiretrovirals require careful monitoring for reduced contraceptive effect.

Food and Lifestyle Interactions

• Alcohol: Moderate consumption does not diminish contraceptive efficacy but can increase liver metabolism and exacerbate side-effects such as nausea.
• Smoking: Increases thrombotic risk, especially for women over 35 years.
• Caffeine: No direct interaction, but excessive intake may exacerbate headache.
• Driving and machinery: Femilon does not impair psychomotor function; however, severe headache or dizziness should be evaluated before operating vehicles.

How to Take Femilon

• Standard regimen: One tablet each day, preferably at the same time, for 21 consecutive days followed by a 7-day hormone-free interval during which withdrawal bleeding occurs.
• Dosage strength: Each tablet contains 0.15 mg ethinylestradiol and 0.02 mg desogestrel (the only strength marketed in the UK).
• Administration: Swallow the tablet whole with water; do not crush or chew. The tablet may be taken with or without food.
• Missed dose:
• If a single tablet is missed and it is ≤ 12 hours late, take it as soon as remembered and continue with the next tablet at the usual time.
• If > 12 hours have passed, take the missed tablet immediately, discard any subsequent tablets for that day, and use a backup method (e.g., condoms) for the next 7 days.
• Overdose: Symptoms may include nausea, vomiting, breast tenderness, and heavy menstrual bleeding. Seek urgent medical attention; treatment is symptomatic, and activated charcoal may be considered if ingestion was recent.
• Discontinuation: Femilon can be stopped at any time. If cessation is planned, a backup method should be used for at least 7 days. No tapering is required, but some women experience a brief return of pre-menstrual symptoms.

Special population dosing: No dosage adjustment is recommended for renal or hepatic impairment, but clinicians should evaluate the risk-benefit profile in severe organ dysfunction.

Monitoring and Follow-Up

• Blood pressure should be measured before initiation and periodically thereafter, especially in smokers or women with a history of hypertension.
• Weight and BMI monitoring is advisable, as hormonal contraceptives can cause modest fluid retention.
• Gynecologic review after the first 3 months to assess cycle regularity, breakthrough bleeding, or any adverse events.
• Laboratory tests (liver function tests, lipid profile) are not routinely required but may be ordered if clinically indicated.

Storage and Handling

• Store Femilon tablets at room temperature (15-30 °C), away from excess heat and moisture.
• Keep the bottle tightly closed and out of reach of children and pets.
• Do not expose the tablets to direct sunlight.
• Dispose of unused tablets according to local pharmacy take-back programmes or follow the instructions on the packaging label.

Medication-Specific Glossary

Combined Oral Contraceptive (COC)

A medication that contains both an estrogen and a progestogen, taken orally to prevent ovulation and provide contraceptive protection.

Thromboembolism

Formation of a blood clot that can travel through the bloodstream and block a vessel, potentially causing serious conditions such as deep-vein thrombosis or stroke.

CYP3A4

A liver enzyme that metabolises many drugs, including hormonal contraceptives; substances that induce or inhibit this enzyme can alter contraceptive effectiveness.

Endometrial Transformation

Hormone-induced changes in the uterine lining that make it less suitable for implantation of a fertilised egg.

Cycle Control

The ability of a contraceptive to regulate the length and flow of menstrual periods, reducing irregular bleeding and dysmenorrhoea.

Medical Disclaimer

This article provides educational information about Femilon and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.